1	Effect of Adjunctive Intraoral Balance Appliance in the Usual Care of
2	Patients with Chronic Temporomandibular Joint Disorders using
3	Korean Medicine: Study Protocol for a Randomized Controlled Trial
4	Woo-Chul Shin <sup>1</sup> , Se yun Kim <sup>1</sup> , Whisung Cho <sup>2</sup> , Jaehyun Park <sup>2,3</sup> , Hyungsuk Kim <sup>1,2</sup> , Won-
5	Seok Chung <sup>1,2</sup> , Mi-Yeon Song <sup>1,2</sup> , Jae-Heung Cho <sup>1,2,*</sup>
6	
7	<sup>1</sup> Department of Korean Medicine Rehabilitation, College of Korean Medicine, Kyung Hee University
8	Korean Medicine Hospital, Seoul, Republic of Korea
9	<sup>2</sup> Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea
10	<sup>3</sup> Miall Hospital of Korean Medicine
11	
12	*Correspondence:
13	Jae-Heung Cho, Department of Clinical Korean Medicine Graduate School, Kyung Hee
14	University, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul, Republic of Korea
15	vetkong95@hanmail.net
16	
17	
18	
19	
20	

1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 21 ABSTRACT

#### 22 Introduction

Temporomandibular disorders (TMD) are a group of conditions that affect the temporomandibular joint, masticatory muscles, and associated structures, often leading to pain, dysfunction, and a significant impact on quality of life. Epidemiological studies have estimated that up to 75% of the population in the United States exhibit at least one sign of TMD. Although conservative treatments such as acupuncture and occlusal splints have been recommended, evidence for their effectiveness remains inconclusive, and the combined effects of these interventions are not well understood.

This study aims to compare the efficacy of an intraoral balance appliance (IBA) combined with standard Korean medicine care versus Korean medicine care alone in patients with chronic, painful TMD with myalgia.

## 32 Materials and Methods

A single-center, two-arm, parallel, evaluator-blinded, randomized controlled trial (RCT) with a 1:1 allocation ratio will be designed to test the interventions. Seventy-six TMD patients with myalgia will be recruited and randomized. The Interventions will include manual acupuncture and physical therapy in both groups, with the addition of IBA in the treatment group.

#### 37 Discussion

38 The outcomes will be measured using various scales such as the numeric rating scale for pain and 39 bothersomeness, jaw functional limitation scale, and quality of life indicators.

## 40 Conclusion

The trial is expected to provide evidence of the efficacy of combining the usual Korean medicine care and IBA in managing chronic TMD myalgia. Despite certain limitations such as the short intervention period and lack of standardized splint therapy, this RCT will contribute valuable data to guide the future

- 44 treatment of TMD with myalgia.
- 45 Trial registration: Clinical Research information Service (CRiS) ID: KCT0008906. Registered on
- 46 October 30, 2023
- 47 Keywords: temporomandibular disorder, occlusal splint, Korean medicine, Complementary
- 48 therapies

# 63 Introduction

64 The temporomandibular joint (TMJ) is the only bilateral synovial joint in the human body [1]. This allows opening and closing of the mouth for mastication, which is essential for the life-sustaining 65 functions of the body. Temporomandibular disorders (TMD) are a subgroup of craniofacial pain 66 67 problems that involve the TMJ, masticatory muscles, and associated head and neck musculoskeletal 68 structures [2]. Temporomandibular disorders can lead to a cluster of symptoms, including jaw pain, 69 facial pain, headache, and associated psychological and psychosocial problems. Given the varied 70 subgroups of symptoms and signs present in TMD, the etiological factors are recognized as 71 multifactorial, encompassing biological, behavioral, environmental, social, emotional, and cognitive 72 influences, either independently or in combination, contributing to the disorder. According to the diagnostic criteria for TMD (DC/TMD), TMD can be classified as either intra- or extra-articular [3]. 73 74 Extra-articular conditions, which usually involve musculature problems surrounding the TMJ, are the 75 most common causes of TMD, accounting for at least 50% of TMD cases [4]. Additionally, among the 76 various signs and symptoms of TMD, pain-related TMD is more common and significantly affects an individual's daily activities. Epidemiological studies have shown that 40-75% of the population 77 78 exhibits at least one of the signs of TMD [2]. Additionally, the OPPERA project (Orofacial Pain: Prospective Evaluation and Risk Assessment) estimated the annual incidence of TMD to be 79 approximately 4% in the US population [5], with a 20.4% prevalence of chronic pain, indicating that 80 81 TMD represents a major public health burden.

One suggested initial approach for TMD, particularly of myogenous origin, is conservative management because of its multifaceted causes and unknown precise pathogenesis. Conservative treatment modalities include counseling, medication, exercise, occlusal splints, and acupuncture [4]. Among the treatment modalities, acupuncture has garnered widespread adoption, particularly in East Asian countries, owing to its relatively few adverse effects and notable analgesic efficacy. Multiple controlled trials have reported the efficacy of acupuncture on pain conditions, such as myofascial pain,

tension headache, and fibromyalgia. [6] Similar to myofascial pain conditions, TMD with myalgia is 88 89 often associated with tender points in related masticatory muscles. Systematic reviews have shown that 90 acupuncture reduces the signs and symptoms of myofascial TMD pain; however, the quality of the 91 included studies was low [7, 8]. Another conservative treatment option is occlusal splints. One of the 92 main pathologies of TMD is mechanical displacement, usually within the disc-condyle relationship. 93 Various splints are used to restore static and dynamic occlusions, relax the relevant musculature, and 94 reduce physiological stress in joint structures [9]. Several systematic reviews have indicated the benefits of occlusal splints in treating TMD [10]. Moreover, a recent network meta-analysis demonstrated that 95 occlusal splints are one of the most effective treatment modalities for TMD, yielding significant benefits 96 97 in both short and intermediate terms [11].

Despite the reported advantages of various treatments for TMD, a definitive consensus regarding the
most efficacious treatment is still lacking as insufficient conclusive evidence is unavailable.
Consequently, a multidisciplinary approach is usually recommended in clinical practice [12]; however,
many interventions have not yet been rigorously tested.

We aim to compare the efficacy of incorporating an intraoral balance appliance (IBA) alongside the usual care for patients with chronic painful TMD using Korean medicine and evaluate its effectiveness on patient's functional, clinical outcomes (pain, bothersomeness, vertical range of motion (ROM), graded chronic pain scale (GCPS), jaw functional limitation scale (JFLS), patient health questionnaire-9 (PHQ-9), quality of life (EQ-5D-5L), and patient global impression of change (PGIC)), and adverse events (AEs).

108

# 109 Materials and methods

## 110 Trial design

111 This is a single-center, two-arm, parallel, evaluator-blind randomized controlled trial with a 1:1

allocation ratio. The study will be performed at Kyung Hee University Medical Center, Korean
Medicine Hospital, Korea. The reporting of the protocol will adhere to the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) (S1 table) [13]. The trial follows the Consolidated
Standards of Reporting Trials (CONSORT) reporting guidelines and the Standards for Reporting
Interventions in Clinical Trials of Acupuncture (STRICTA) recommendations (S2 table) [14].

117

# 118 Ethics approval

Ethical approval was obtained from the Institutional Review Board of Kyung Hee University Korean Medicine Hospital Institutional Review Board (IRB number: KOMCIRB 2023-06-001). We will obtain informed consent from each eligible participant, and collect data anonymously to maintain privacy. This study will be conducted in full conformity with the 1964 Declaration of Helsinki and all subsequent revisions and in accordance with the Good Clinical Practice Guidelines. The protocol will be registered at the Clinical Research information Service (CRiS), Republic of Korea, on October 30, 2023 (CRiS number KCT0008906) before enrollment of the first participant.

126

## 127 Sample size calculation

128 This study is a prospective study that will compare the effects of different IBA. Referring to a previous 129 study that compared treatments for painful masticatory muscles [15], an appropriately powered full-130 scale sample size will be estimated using the mean difference of the numeric rating scale (NRS) for 131 pain owing to TMD with myalgia between groups at the primary endpoint. The effect size d according to the change in the reference study is 0.74, and with 80% power, 0.05 alpha, and a two-sided test, the 132 number of samples required for each group will be 30. The total sample size required, when considering 133 a dropout rate of 20%, will be 76 participants, with 38 participants in each group. The sample size will 134 135 be determined using G\*Power 3.1.7 software.

#### 136

## 137 Methods of recruitment

- 138 Recruitment will be accomplished by issuing press releases about the study, advertisements in free
- 139 newspapers, and displaying posters within and outside Kyung Hee University Medical Center Korean
- 140 Medicine Hospital in Seoul, Korea. The estimated recruitment period is 12 months.

141

## 142 Eligibility criteria

- 143 The inclusion criteria will be as follows:
- 144 1) Participants aged between 19–70 years on the date of signing the informed consent form.
- 145 2) Participants with unilateral or bilateral TMJ pain.
- Participants with a NRS of ≥4 at the site of TMJ pain (based on the side with more pain for
  participants with bilateral pain).
- 148 4) Participants with persistent or intermittent TMJ pain for  $\geq$ 3 months.
- 149 5) Participants with a diagnosis of TMD with myalgia according to the DC/TMD diagnostic criteria.
- 6) Participants who voluntarily agree to participate in the study and sign a written informed consentform prior to any study-related procedures.
- 152
- 153 The exclusion criteria will be as follows:
- 154 1) Current pain episode caused or exacerbated by traumatic injuries such as motor vehicle accidents.
- 155 2) Individuals who do not meet the diagnosis of TMD with myalgia according to the DC/TMD
   156 diagnostic criteria.

157	3)	Undergone surg	ery related to TMJ.
-----	----	----------------	---------------------

158	4)	Concomitant medical conditions that may interfere with the efficacy of treatment or interpretation
159		of results (e.g., rheumatoid arthritis, tumor, stroke, and myocardial infarction)
160	5)	Participants currently taking steroidal agents, immunosuppressants, psychiatric medications, and
161		other medications that may affect the results of the trial.
162	6)	Participants who have taken medications that may affect pain, such as non-steroidal anti-
163		inflammatory drugs within the past week, or have applied orthodontic appliances in the past two
164		weeks, regardless of the condition.
165	7)	Participants who are pregnant, planning to become pregnant, or breastfeeding women.
166	8)	Participated in another clinical trial within one month before the date of enrollment, or plans to
167		participate in another clinical trial during the study participation and follow-up period.
168	9)	Other reasons deemed by the investigator that may present difficulties to participate in the trial.
169		
170	Partie	cipants in the trial will voluntarily sign the written informed consent forms in accordance with the
171	Decla	aration of Helsinki and Guidelines for Good Clinical Practice. The consent form will be collected
172	by th	e participating Korean medicine doctors (KMDs) or a participating clinical research coordinator.
173		
174	Rano	domization and allocation strategy
175	Rand	omization will be conducted using computer-generated random numbers. A statistician who is not
176	invol	ved in the intervention process will generate computer-generated random numbers. Blocked
177	rando	omization will be used to ensure a balance between the two groups, with the block size kept
178	confi	dential from those involved in patient enrollment or intervention assignment. The randomized

numbers will be assigned to screen the participants in the order of recruitment. The designated
investigator will provide the intervention arm to the practitioners. The generated random numbers will
be sealed in an envelope and stored by an investigator who will not engage with the participants.

182

# 183 Dropout and withdrawal

184 If any participants voluntarily withdraw their consent at any point during the study or if an adverse 185 event (AE) that is considered harmful to the participants is observed, the investigator will temporarily 186 or permanently discontinue the study for the respective participants. Detailed reasons for any interrupted 187 study trials will be recorded by the investigator. If early withdrawal owing to an AE occurs, appropriate treatment will be provided and the investigator will continue to monitor the participant until the AE 188 resolves. In case of consent withdrawal, no further follow-up will be conducted. The investigator may 189 190 also terminate the study if the participant receives a procedure, medication, or other treatments that could affect the study without permission. Study participants who withdraw before treatment initiation 191 192 will be considered screening failures.

193 The investigators will make every effort to obtain information about the patients who drop out and 194 record the reason for discontinuation in the electronic case report forms (eCRF).

195

#### 196 Blinding

This will be an open-label study with participants and practitioners being aware of treatment allocation.
Only the outcome evaluator will be blinded to the intervention arm. Therefore, unblinding will be
unnecessary in any circumstances.

200

# 201 Participants' timeline

202 The duration of the study will be four weeks. A timeline of this study is shown in Fig 1.

## 203 Fig 1. SPIRIT schedule of enrollment, interventions, and assessments.

204

#### 205 Interventions

Participants will be randomized into treatment and control groups. Both groups will receive the usual care of Korean medicine consisting of manual acupuncture and physical therapy. The treatment group will receive additional IBA (JinBiotech®, Cheonan, Korea). Owing to the inherent nature of splint therapy, creating a placebo group is fundamentally impractical; therefore, it will not be included in this study. Acupuncture and physical therapy will be administered twice a week for three weeks, with a total of six treatment sessions for both the treatment and control groups.

Manual acupuncture will be performed at four essential acupuncture points: Xiaguan (ST7), Jiache (ST6), Ermen (TE21), and Yifeng (TE17). Additional 'ashi points,' which are tender points in associated musculature, will be determined by the participating KMDs. Manual acupuncture will be administered using disposable sterile stainless-steel needles ( $40 \times 0.25$  mm; Dong-bang Medical,

Seongnam, Korea) after skin sterilization with the participants lying face down. The needles will be inserted perpendicularly or obliquely, depending on the acupuncture point, to a depth of 5–30 mm, and left in place for 15 min. More detailed procedures based on STRICTA are attached in S2 Table.

Infrared radiation (IR 3000; Haedong Medical, Ulsan, Korea) will be simultaneously applied to thearea where acupuncture treatment has been performed for 15 min.

Physical therapy will be performed using an interferential current therapy (ICT) device (Nihon Medix Model 5402, Japan). The participants will be asked to lie down in the prone position with the cervical area unclothed. Four self-adhesive 6 x 6 cm electrodes will be placed using a crossed pattern in the lower cervical area. The intensity will be varied according to the individual tolerance. The ICT

stimulation will be applied for 15 min per session. The participants will be instructed to immediatelyreport any discomfort during treatment.

The participants in the treatment group will be instructed to apply IBA for a minimum of 6 h a day over three weeks. The IBA will be positioned in the participant's mouth with the tongue tag portion facing upward, and the outer centerline of the appliance will be aligned with the middle of the upper teeth. The participants will be instructed to gently place their teeth on the occlusal plane without clenching or applying force to their molars while wearing the device. A GMP certification (KTR-AABB-16978) has been obtained for the device from the Korea Testing & Research Institute.

During the treatment period (Weeks 1–3), any procedure or medication aimed directly at relieving painful TMD will be prohibited. However, ibuprofen will be allowed as a relief medication during the study for all participants, and the dosage will be self-reported.

236 Concomitant care will be allowed for the subsequent follow-up period (week four). Any treatment237 administered during the follow-up period will be documented during the last visit.

238

## 239 Practitioner background

Acupuncture treatments will be conducted by KMDs licensed by the Korean Ministry of Health and Welfare, who specialize in rehabilitation medicine of Korean medicine and have at least five years of

clinical experience. Techniques for the entire treatment procedure will be standardized by practitioners.

243

#### 244 Measurements

At screening, the assessment will include demographics (age and sex), anamnesis (underlying illness

and medical and treatment histories), physical examination (muscle palpation), and ROM of the TMJ.

247 The database will include the following information after enrollment and allocation:

248 1) Patient characteristics: height (cm), weight (kg), and vital signs (body temperature, blood pressure,
249 and pulse rate).

250 2) Outcomes: NRS for pain and bothersomeness, vertical ROM of the TMJ, GCPS, JFLS, PHQ-9,

EQ-5D-5L, PGIC, patient satisfaction, credibility and expectancy, and AE.

The primary outcome of the study will be the NRS score for pain and bothersomeness assessed at the final visit at week four. Participants will select a number between 0 and 10 that best represents their current pain intensity, with 0 indicating no pain and 10 denoting the most severe pain imaginable. In cases where participants complain of pain in both TMJs, the side with the most severe pain will serve as the reference.

The ROM of the TMJ is the vertical ROM measured with a ruler as the maximum range of voluntary opening without pain. The test will be performed in accordance with the clinical examination protocol provided by the International DC/TMD consortium [16].

The GCPS-1-month version uses the same item structure as the original GCPS-6-month scale, published in 1992. The DC/TMD includes the GCPS-1-month version because of its recognized clinical utility in assessing pain persistence. The scale has been evaluated for reliability and validity, and it consists of

seven items that assess pain intensity and pain-related disabilities over the past 30 days [3].

The JFLS is a global measure of functional limitation derived from the Research Diagnostic Criteria for TMD Checklist and the Mandibular Functional Impairment Questionnaire. This scale comprises 20 items that assess limitations in mastication, jaw mobility, and verbal and emotional expressions. Previous studies have reported its reliability and validity [17].

The PHQ-9 has the advantage of being aligned with the diagnostic criteria for depression in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders with good sensitivity and specificity. The measurement is short and practical, with only nine items. The reliability and validity of the Korean version of the PHQ-9 have been validated in numerous studies [18].

The EQ-5D-5L, developed in 2010, is a five-level version of the EQ-5D and is a broadly used generic multi-attribute health utility instrument. Composed of five items, the EQ-5D-5L is currently available in >130 languages, and it demonstrated improved psychometric properties over the EQ-5D-3L version. [19]

The PGIC and patient satisfaction questionnaires will be used to assess the subjective responses of patients to symptom changes after treatment. The PGIC is a seven-point transition scale used to evaluate patients' perceptions of their overall change in symptoms after intervention [20]. The patient satisfaction questionnaire consists of three questions, each rated on a nine-point Likert scale. Additionally, the nine-point Likert scale will be used to assess the participants' credibility and expectancy toward the treatment.

282

#### **Data collection and management**

284 Electronic case report forms will be developed and validated to collect all study-related information. 285 The designated site staff will document participant data in a local participant file. The investigators will manage and conduct quality control of the data according to their standard operating procedures. The 286 287 participant files will serve as source data for the study, and the data will be entered into the eCRF. The 288 eCRF platform will be provided by the National Clearinghouse for Korean Medicine (NCKM). To ensure the integrity of the study data, only one individual will be allowed to assess the eCRF at a time, 289 290 and both the eCRF and supporting documents will be subjected to cross-checking. Monitoring will be scheduled three times during the study: initial monitoring upon the selection of the initial patient, 291 292 interim monitoring at any point during the study duration, and final monitoring after the study. Monitoring will be conducted by personnel independent of the study process. All documents related to 293 the study will be kept in a designated secured storage inside the study management department. All 294 295 records will be retained for three years after the end of the clinical study. After the retention period, the 296 records will be terminated to ensure confidentiality.

297

## 298 Statistical methods

299 Sociodemographic characteristics, treatment credibility, and expectations will be assessed for each group. Primary analysis will involve an intention-to-treat approach, while per-protocol analysis will be 300 301 conducted simultaneously if necessary. To compare the differences between the two groups, Student's t-test will be used for continuous variables, and the chi-square test or Fisher's exact test will be 302 303 performed for categorical variables. The efficacy variables will be the difference in the change in 304 continuous outcomes between the two groups from baseline to each evaluation time point. A repeated-305 measures analysis of variance (RM-ANOVA) or a mixed model for repeated data will be performed to 306 test for differences in trend changes across visits. Additionally, an analysis of covariance (ANCOVA) 307 will be performed using the baseline values of each variable and covariate factors that are statistically 308 different between the groups at baseline, with the group as a fixed factor. The analysis will examine the 309 proportion of patients whose pain NRS scores decrease by half or more from baseline at each evaluation 310 time point. A Kaplan–Meier survival analysis will assess the duration from randomization to achieving a reduction in NRS pain scores by less than half, and the resulting curves will be compared using the 311 log-rank test. A Cox model will be employed to compare the rate of TMJ pain reduction to less than 312 313 half by calculating the hazard ratio. Any missing data from participants who drop out will be handled 314 mainly by multiple imputations, and the last observation carried forward will be used for the sensitivity 315 analysis.

The significance level for all the analyses will be set at 0.05. All the statistical analyses will be performed using the SAS version 9.4 statistical package (SAS Institute, Cary, NC, USA).

Subgroup analyses will be conducted, if necessary. No interim analyses will be planned for the study as the sample size calculation will be tailored for the treatment period, which will make it improbable to achieve a statistically significant difference between the groups before the primary endpoint.

321

## 322 **Confidentiality**

323 Investigators with direct access to the source data will take all necessary precautions to ensure the confidentiality of the information, and participant confidentiality will be strictly maintained as far as 324 possible under the law and hospital policy. Each participant that will be enrolled in the study will be 325 encrypted by assigning a unique identification number to protect the confidentiality of personal 326 327 information. The medical information of participants obtained in the study will be confidential and may 328 be disclosed to third parties, as permitted by the patient's signed consent form. Additionally, medical information may be provided for treatment purposes to the appropriate healthcare personnel responsible 329 330 for patient welfare. To the extent necessary, data from the study may be presented upon request by 331 monitoring personnel or by the Institutional Review Board (IRB) of the clinical research organization.

332

## 333 Adverse event reporting and harms

In a clinical study, an AE is denoted as an undesirable and unintended sign, symptom, or disease that occurs after a procedure and is not necessarily causally related to the procedure. Serious AE (SAE) are as follows:

- 1) Causes death or is life-threatening.
- 2) Requires hospitalization or extended hospitalization.

339 3) Causes persistent or significant disability or reduced functioning.

340 4) Other medically significant circumstances.

341 Phenomena expected to be AE will be fully recorded in detail (signs, symptoms, onset date, duration,

etc.), and evaluation of the AE will be recorded in a separate case report form by the investigator. The

343 causal relationship with the intervention will be evaluated according to the World Health Organization-

- Uppsala Monitoring Centre causality categories [21]. The degree of symptoms will be evaluated using
  the three-level classification method of Spilker [22].
- 346

# 347 **Protocol amendments**

348 If changes to the study protocol are required, all changes will be approved by the IRB of the clinical 349 research organization before implementation, except for those necessary to eliminate immediate 350 participant risk and administrative changes.

351

# 352 Trial status and dissemination plans

Currently, the study protocol, eCRF, and relevant documents are being reviewed before trial initiation.
The protocol is version 2.3 (2023-08-04). The estimated date of recruitment completion is December
2024.

The results of this study will be actively disseminated through manuscript publications and conference presentations. Regardless of whether the study is completed or prematurely terminated, the clinical study report will be provided to the IRB of the clinical research organization.

359

# 360 **Discussion**

In 1934, Dr. James Costen published a paper describing a syndrome characterized by ear pain, tinnitus, vertigo, and limited jaw movement, which he attributed to abnormalities in the TMJ. Despite differences in modern terminology, this syndrome is considered one of the earliest descriptions of what we now recognize as TMD [23]. Almost a century has passed, yet the prevalence of TMD has remained fairly consistent or has even increased over the years with no definitive treatment, posing a significant burden both individually and globally [24].

367 Despite the promising efficacy reported by several systematic reviews of various conservative 368 treatments for TMD, such as acupuncture, occlusal splinting, photomodulation, laser, biofeedback, 369 cognitive behavioral training, hypnosis, botulinum toxin A, exercise, and medication, many studies 370 have reported conflicting results with insufficient evidence [25]. However, recent guidelines for the 371 management of TMD recommend acupuncture and splint therapy because conservative approaches 372 should be pursued first [26]. Clinically, acupuncture is used in various forms including traditional 373 acupuncture, dry needling, electroacupuncture, warm-needle acupuncture, and laser acupuncture. 374 Regardless of the study type, recent systematic reviews have revealed that acupuncture, whether used 375 independently or as an adjunct to other treatments, can significantly improve the effect rate and pain intensity in patients with TMD compared with inactive controls, although the quality of the evidence 376 377 was low [7, 27]. A systemic review comparing conservative therapeutic modalities for TMD concluded 378 that occlusal splints, alone or in combination with other interventions, had a positive effect on short-379 term TMD pain reduction [25]. However, owing to the inherent heterogeneity of splint studies, such as 380 the various types of splints used, delivery methods, and study designs, it is challenging to draw firm 381 conclusions [28]. Few studies have assessed the efficacy of combining acupuncture with splint therapy 382 for the treatment of TMD. One study with a design similar to ours compared acupuncture versus 383 acupuncture plus splint therapy for painful TMD over four weeks [29]. Although the combination of 384 interventions did not show significant differences between the groups, the splint group demonstrated an 385 accelerated decrease in pain and improved short-term efficacy.

The potential limitations of the study are as follows: 1) the intervention period was short, with no longterm follow-up evaluation scheduled, which means that only short-term effects can be determined; 2) since there is no standardized splint therapy for the treatment of painful TMD, the results of this study will be confined to a specific splint, the IBA, and cannot be extrapolated to other types of splints. Nevertheless, this randomized, assessor-blind, controlled trial will provide high-quality data on the efficacy of combined treatment with acupuncture and the IBA for TMD with myalgia and may help to guide future directions for the treatment of TMD with myalgia.

#### 393

394	Abbreviations	
395	AE	Adverse event
396	ANCOVA	Analysis of covariance
397	CONSORT	Consolidated standards of reporting trials
398	CRiS	Clinical Research information Service
399	DC/TMD	Diagnostic criteria for temporomandibular disorders
400	eCRF	Electronic case report form
401	EQ-5D-5L	5-Level EuroQol-5 dimension
402	GCPS	Graded chronic pain scale
403	IBA	Intraoral balance appliance
404	IRB	Institutional review board
405	JFLS	Jaw functional limitation scale
406	KMD	Korean medicine doctor
407	NCKM	National Clearinghouse for Korean Medicine
408	NRS	Numeric rating scale
409	PHQ-9	Patient health questionnaire-9
410	PGIC	Patient global impression of change
411	SAE	Severe adverse event
412	STRICTA	Standards for reporting interventions in clinical trials of acupuncture
413	TMD	Temporomandibular joint disorder
414	TMJ	Temporomandibular joint
415	RM-ANOVA	Repeated measure analysis of variance

416	ROM	Range of motion
417		
418	Author's contribution	ons
419	All the authors have	read and approved the final manuscript. Conceptualization: WCS, SYK, and JHC; methodology: WCS,
420	SYK, and JHC; writi	ing-original draft preparation: WCS and JHC; writing-review and editing: WCS, WC, JP, HK, WSC,
421	MYS, and JHC; visua	alization and project administration: JHC.
422		
423	Funding	
424	This research was sup	oported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry
425	Development Institut	e (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (grant number: RS-2022-
426	KH127610).	
427		
428	Availability of data	and materials
429	No datasets were gene	erated or analyzed during the current study. All relevant data from this study will be made available upon
430	study completion.	
431		
432	Competing interest	
433	The authors declare n	o competing interests.
434		
435	Reference	
436	1. Gao W, Lu J, G	ao X, Zhou J, Dai H, Sun M, et al. Biomechanical effects of joint disc perforation on the
437	temporomandibular	r joint: a 3D finite element study. BMC Oral Health. 2023;23(1):943.
438	2. Scrivani SJ, Keit	h DA, Kaban LB. Temporomandibular disorders. N Engl J Med. 2008;359(25):2693-705.
439	3. Schiffman E, C	Dhrbach R, Truelove E, Look J, Anderson G, Goulet JP, et al. Diagnostic Criteria for

- Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the
  International RDC/TMD Consortium Network\* and Orofacial Pain Special Interest Groupdagger. J Oral Facial
  Pain Headache. 2014;28(1):6-27.
- 443 4. Gauer RL, Semidey MJ. Diagnosis and treatment of temporomandibular disorders. Am Fam Physician.
  444 2015;91(6):378-86.
- 5. Slade GD, Ohrbach R, Greenspan JD, Fillingim RB, Bair E, Sanders AE, et al. Painful Temporomandibular
  Disorder: Decade of Discovery from OPPERA Studies. J Dent Res. 2016;95(10):1084-92.
- 6. Kelly RB, Willis J. Acupuncture for Pain. Am Fam Physician. 2019;100(2):89-96.
- 448 7. Di Francesco F, Minervini G, Siurkel Y, Cicciu M, Lanza A. Efficacy of acupuncture and laser acupuncture in
- temporomandibular disorders: a systematic review and meta-analysis of randomized controlled trials. BMC Oral
  Health. 2024;24(1):174.
- 8. Fernandes AC, Duarte Moura DM, Da Silva LGD, De Almeida EO, Barbosa GAS. Acupuncture in
  Temporomandibular Disorder Myofascial Pain Treatment: A Systematic Review. J Oral Facial Pain Headache.
  2017;31(3):225-32.
- 9. Gupta AK, Gupta R, Gill S. Effectiveness of Vitamin D along with Splint therapy in the Vit D deficient patients
  with Temporomandibular disorder-A Randomized, double-blind, placebo-controlled clinical trial. J Indian
  Prosthodont Soc. 2022;22(1):65-73.
- 457 10. Al-Moraissi EA, Farea R, Qasem KA, Al-Wadeai MS, Al-Sabahi ME, Al-Iryani GM. Effectiveness of occlusal
  458 splint therapy in the management of temporomandibular disorders: network meta-analysis of randomized
  459 controlled trials. Int J Oral Maxillofac Surg. 2020;49(8):1042-1056.
- 11. Al-Moraissi EA, Conti PCR, Alyahya A, Alkebsi K, Elsharkawy A, Christidis N. The hierarchy of different
  treatments for myogenous temporomandibular disorders: a systematic review and network meta-analysis of
  randomized clinical trials [published correction appears in Oral Maxillofac Surg. 2021 Nov 5;:]. *Oral Maxillofac Surg.* 2022;26(4):519-533.
- 464 12. Costa YM, Conti PC, de Faria FA, Bonjardim LR. Temporomandibular disorders and painful comorbidities:

465 clinical association and underlying mechanisms. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;123(3):288466 297.

- 467 13. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for
- 468 protocols of clinical trials. *BMJ*. 2013;346:e7586. Published 2013 Jan 8. doi:10.1136/bmj.e7586
- 469 14. MacPherson H, Altman DG, Hammerschlag R, et al. Revised STandards for Reporting Interventions
- 470 in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med.
- 471 2010;7(6):e1000261. Published 2010 Jun 8. doi:10.1371/journal.pmed.1000261
- 472 15. Wright E, Anderson G, Schulte J. A randomized clinical trial of intraoral soft splints and palliative treatment
- 473 for masticatory muscle pain. J Orofac Pain. 1995;9(2):192-199.
- 474 16. Ohrbach R, Gonzalez Y, List T, Michelotti A, Schiffman E. Diagnostic Criteria for Temporomandibular
- 475 Disorders (DC/TMD) Clinical Examination Protocol: Version 02June2013. <u>www.rdc-tminternational.org</u>
- 476 Accessed on March 6, 2024.
- 477 17. Pattanaik S, John MT, Chung S, Keller S. Differential Item Functioning of the Jaw Functional Limitation
  478 Scale. J Oral Facial Pain Headache. 2023;37(1):33-46.
- 479 18. Park KY. Reliability, Validity and Clinical Usefulness of the Korean Version of the Patient Health
  480 Questionnaire-9 (PHQ-9). Global Health Nurs. 2017;7(2):71-78.
- 481 19. Feng YS, Kohlmann T, Janssen MF, Buchholz I. Psychometric properties of the EQ-5D-5L: a systematic
  482 review of the literature. Qual Life Res. 2021;30(3):647-673.
- 20. Domingues L, Pimentel-Santos FM, Cruz EB, et al. Is a combined programme of manual therapy and exercise
  more effective than usual care in patients with non-specific chronic neck pain? A randomized controlled trial. Clin
  Rehabil. 2019;33(12):1908-1918.
- 486 21. antikul C, Dhana N, Jongjarearnprasert K, Visitsunthorn N, Vichyanond P, Jirapongsananuruk O. The utility
- 487 of the World Health Organization-The Uppsala Monitoring Centre (WHO-UMC) system for the assessment of
- 488 adverse drug reactions in hospitalized children. Asian Pac J Allergy Immunol. 2008;26(2-3):77-82.

- 489 22. Spilker, B. Interpretation of Adverse Reactions. In Guide to Clinical Trials; Raven Press, Ltd.: New York,
  490 NY, USA, 1991; pp. 565–587.
- 491 23. Michael LA. Jaws revisited: Costen's syndrome. Ann Otol Rhinol Laryngol. 1997;106(10 Pt 1):820-822.
- 492 24. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health
- 493 Care Services; Board on Health Sciences Policy; Committee on Temporomandibular Disorders (TMDs): From
- 494 Research Discoveries to Clinical Treatment; Yost O, Liverman CT, English R, et al., editors. Temporomandibular
- 495 Disorders: Priorities for Research and Care. Washington (DC): National Academies Press (US); 2020 Mar 12.
- 496 Appendix C, Prevalence, Impact, and Costs of Treatment for Temporomandibular Disorders. Available from:
- 497 https://www.ncbi.nlm.nih.gov/books/NBK557996/
- 498 25. Tournavitis, A., Sandris, E., Theocharidou, A., Slini, T., Kokoti, M., Koidis, P., & Tortopidis, D. (2023).
- 499 Effectiveness of conservative therapeutic modalities for temporomandibular disorders-related pain: a systematic
- 500 review. Acta odontologica Scandinavica, 81(4), 286–297.
- 501 26. Busse, J. W., Casassus, R., Carrasco-Labra, A., Durham, J., Mock, D., Zakrzewska, J. M., Palmer, C., Samer,
- 502 C. F., Coen, M., Guevremont, B., Hoppe, T., Guyatt, G. H., Crandon, H. N., Yao, L., Sadeghirad, B., Vandvik, P.
- 503 O., Siemieniuk, R. A. C., Lytvyn, L., Hunskaar, B. S., & Agoritsas, T. (2023). Management of chronic pain
- associated with temporomandibular disorders: a clinical practice guideline. *BMJ (Clinical research ed.)*, 383,
  e076227.
- 506 27. Park EY, Cho JH, Lee SH, Kim KW, Ha IH, Lee YJ. Is acupuncture an effective treatment for
- temporomandibular disorder?: A systematic review and meta-analysis of randomized controlled trials. Medicine
  (Baltimore). 2023;102(38):e34950.
- 509 28. Fricton J. (2006). Current evidence providing clarity in management of temporomandibular disorders:
  510 summary of a systematic review of randomized clinical trials for intra-oral appliances and occlusal therapies. The
- 511 journal of evidence-based dental practice, 6(1), 48–52.
- 512 29. Sant'Anna CBM, Caxias FP, Zuim PRJ, Januzzi MS, Silva EVFD, Turcio KHL. Treatment of Masticatory
- 513 Muscle Pain with Acupuncture: Is It Necessary to Associate with Occlusal Splints?. J Acupunct Meridian Stud.
  514 2021;14(3):89-94.

medRxiv preprint doi: https://doi.org/10.1101/2024 06.18.24309139; this version posted June 21, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.								
Time point	Screening Treatment							Follow-Up
Thie point	Week-1	Week 1		Week 2		Week 3		Week 4
Visit	1	2	3	4	5	6	7	8
Eligibility screening	х							
Written Informed consent	х							
Vital signs	-							
Sociodemographic characteristics,								
medical history	х							
(e.g. TMJ pain, medication history)								
DC/TMD test & analysis	Х							
Randomized allocation		х						
Credibility and Expectancy		х						
Intervention		-						
NRS of TMJ pain & bothersomeness	•							>
TMJ ROM								
(maximum mouth opening)		-						
GCPS-1 month		х						х
JFLS		х						х
PHQ-9		х						Х
EQ-5D-5L		х						Х
PGIC		х						Х
Patient satisfaction								Х
Adverse events			•					

# Figure